From Novel Biotechnology Platform to Globally Competitive Cancer Company: Proacta Inc.

8,00 $50,00 $

CASE STUDY. This decision-based case focuses on whether Proacta should raise more funds within New Zealand alone, syndicate a venture capital round with international investors, or seek a trade sale of the company.

Effacer

Pour acheter une License d'enseignement, vous devez vous enregistrer et être approuvé par notre administration.

Description

From Novel Biotechnology Platform to Globally Competitive Cancer Company: Proacta Inc.: Abstract

Proacta Inc., a private New Zealand-based biotechnology start-up focused on developing novel cancer therapeutics, faced a critical decision in 2004. Preclinical experiments of the company’s lead compound, PR-104, had produced promising results in prostate cancer and other solid tumours models, suggesting a potential path for clinical development towards commercial approval. The company was started by its scientific founders and had secured initial venture capital financing that opened up the potential to advance the technology to human clinical trials, which would require significant additional capital. In urgent need of additional funding to advance into human clinical trials, Proacta’s CEO visited 35 venture capital companies and alliance partners internationally. This decision-based case focuses on whether Proacta should raise more funds within New Zealand alone, syndicate a venture capital round with international investors, or seek a trade sale of the company.

Additional information

Teaching notes are available for teachers only. Contact the HEC Montréal Case Centre for more information.

Informations complémentaires

Année

Annexe

Éditeur

Format

Industrie

Institution

Langue

Licence

,

Nombre de pages

Notes pédagogiques

Numéro centre de cas

Parution

Taille

Avis

Il n’y a pas encore d’avis.

Soyez le premier à laisser votre avis sur “From Novel Biotechnology Platform to Globally Competitive Cancer Company: Proacta Inc.”